載入中
HKSEHealthcareMedical - Devices
最新資料
HK$20.10
−HK$0.24 · -1.18%
Zylox-Tonbridge Medical Technology Co., Ltd. is a global medical device firm specializing in neurovascular and peripheral vascular interventional technologies. Their comprehensive product line for treating ischemic stroke includes the ThromBite Clot Retriever, designed to extract clots from major brain vessels, as well as aspiration and balloon guiding catheters. For peripheral vascular conditions, they offer the ZENFLEX Pro Drug-eluting Stent System for managing complex and recurring symptomatic lesions, the self-expanding ZENFlex Peripheral Stent System for deployment in the iliac, superficial femoral, and proximal popliteal arteries, and drug-coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheters for treating arterial stenoses or blockages in these same regions. Their neurovascular offerings further extend to Ton-Bridge extra soft coils, utilized for the endovascular embolization of intracranial aneurysms and other cerebral vascular malformations like arteriovenous malformations (AVMs) and fistulae. Supporting these are a range of microcatheters (for coiling or selective agent delivery), distal access and intracranial PTA balloon catheters, vascular snares, and IVC filter snare retrieval kits. Established in 2012, Zylox-Tonbridge Medical Technology Co., Ltd. maintains its headquarters in Zhejiang, People's Republic of China.
最新資料
HK$20.10
−HK$0.24 · -1.18%
盤中時間採用HKT。市場資料可能有所延遲。
Zylox-Tonbridge Medical Technology Co., Ltd. is a global medical device firm specializing in neurovascular and peripheral vascular interventional technologies. Their comprehensive product line for treating ischemic stroke includes the ThromBite Clot Retriever, designed to extract clots from major brain vessels, as well as aspiration and balloon guiding catheters. For peripheral vascular conditions, they offer the ZENFLEX Pro Drug-eluting Stent System for managing complex and recurring symptomatic lesions, the self-expanding ZENFlex Peripheral Stent System for deployment in the iliac, superficial femoral, and proximal popliteal arteries, and drug-coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheters for treating arterial stenoses or blockages in these same regions. Their neurovascular offerings further extend to Ton-Bridge extra soft coils, utilized for the endovascular embolization of intracranial aneurysms and other cerebral vascular malformations like arteriovenous malformations (AVMs) and fistulae. Supporting these are a range of microcatheters (for coiling or selective agent delivery), distal access and intracranial PTA balloon catheters, vascular snares, and IVC filter snare retrieval kits. Established in 2012, Zylox-Tonbridge Medical Technology Co., Ltd. maintains its headquarters in Zhejiang, People's Republic of China.
日內區間
目前HK$20.10
52週區間
目前HK$20.10
盤中時間採用HKT。市場資料可能有所延遲。
Zylox-Tonbridge Medical Technology Co., Ltd. is a global medical device firm specializing in neurovascular and peripheral vascular interventional technologies. Their comprehensive product line for treating ischemic stroke includes the ThromBite Clot Retriever, designed to extract clots from major brain vessels, as well as aspiration and balloon guiding catheters. For peripheral vascular conditions, they offer the ZENFLEX Pro Drug-eluting Stent System for managing complex and recurring symptomatic lesions, the self-expanding ZENFlex Peripheral Stent System for deployment in the iliac, superficial femoral, and proximal popliteal arteries, and drug-coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheters for treating arterial stenoses or blockages in these same regions. Their neurovascular offerings further extend to Ton-Bridge extra soft coils, utilized for the endovascular embolization of intracranial aneurysms and other cerebral vascular malformations like arteriovenous malformations (AVMs) and fistulae. Supporting these are a range of microcatheters (for coiling or selective agent delivery), distal access and intracranial PTA balloon catheters, vascular snares, and IVC filter snare retrieval kits. Established in 2012, Zylox-Tonbridge Medical Technology Co., Ltd. maintains its headquarters in Zhejiang, People's Republic of China.
日內區間
目前HK$20.10
52週區間
目前HK$20.10
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（CNY） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 10.57億 CNY | 7.82億 CNY | 5.28億 CNY | 3.34億 CNY | 1.78億 CNY |
| 銷貨成本 | 2.95億 CNY | 2.23億 CNY | 1.43億 CNY | 8142.1萬 CNY | 4603.1萬 CNY |
| 毛利 | 7.63億 CNY | 5.6億 CNY | 3.85億 CNY | 2.53億 CNY | 1.32億 CNY |
| 研究與開發 | 2.47億 CNY | 2.33億 CNY | 2.61億 CNY | 2.33億 CNY | 1.68億 CNY |
| 銷售、一般及管理費用 | 3.16億 CNY | 2.66億 CNY | 2.78億 CNY | 2.49億 CNY | 1.96億 CNY |
| 營業費用 | 5.63億 CNY | 4.99億 CNY | 5.42億 CNY | 4.75億 CNY | 3.5億 CNY |
| 利息收入 | 5463.74萬 CNY | 6734.5萬 CNY | 7904萬 CNY | 9556.5萬 CNY | 1309.4萬 CNY |
| 利息支出 | 99.65萬 CNY | 217.5萬 CNY | 125.1萬 CNY | 72.2萬 CNY | 30.7萬 CNY |
| 折舊和攤銷 | 3726.52萬 CNY | 3784.7萬 CNY | 3588萬 CNY | 2626.8萬 CNY | 1338.2萬 CNY |
| 營業利益 | 1.97億 CNY | 6091.5萬 CNY | −1.57億 CNY | −2.08億 CNY | −2.12億 CNY |
| 淨利 | 2.44億 CNY | 1億 CNY | −7873.4萬 CNY | −1.14億 CNY | −2億 CNY |
公司資料更新於 2026年10月17日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
iShares Core MSCI Emerging Markets ETFIEMG445.19萬0.00%1545.08億 USD0.09%US$76.79-1.66%
Avantis Emerging Markets Equity ETFAVEM23.8萬—276.33億 USD0.33%US$88.89-1.67%
State Street SPDR S&P Emerging Markets Small Cap ETFEWX17.32萬0.03%6.66億 USD0.65%US$69.48-1.19%
iShares MSCI China Small-Cap ETFECNS17.11萬0.29%5918.28萬 USD0.59%US$26.78-0.04%
iShares MSCI Emerging Markets Small-Cap ETFEEMS11.79萬0.03%3.77億 USD0.72%US$73.095-1.10%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM7.91萬0.00%92.26億 USD0.39%US$37.85-1.59%
Dimensional - Emerging Core Equity Market ETFDFAE5.57萬0.00%96.26億 USD0.29%US$37.24-1.66%
Avantis Emerging Markets Small Cap Equity ETFAVEE4.42萬0.03%1.35億 USD0.42%US$66.99-1.27%iShares Core MSCI Emerging Markets ETFIEMGAvantis Emerging Markets Equity ETFAVEMState Street SPDR S&P Emerging Markets Small Cap ETFEWXiShares MSCI China Small-Cap ETFECNSiShares MSCI Emerging Markets Small-Cap ETFEEMSDimensional - Emerging Markets Core Equity 2 ETFDFEMDimensional - Emerging Core Equity Market ETFDFAEAvantis Emerging Markets Small Cap Equity ETFAVEEAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
